Ocaña A - Search Results

1

Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis.

Goldvaser H, Majeed H, Ribnikar D, Šeruga B, Ocaña A, Cescon DW, Amir E. Goldvaser H, et al. Among authors: ocana a. Breast Cancer Res Treat. 2018 Jun;169(3):413-425. doi: 10.1007/s10549-018-4710-5. Epub 2018 Feb 8. Breast Cancer Res Treat. 2018. PMID: 29423899 Review.

2

Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer.

Ocaña A, Hortobagyi GN, Esteva FJ. Ocaña A, et al. Clin Breast Cancer. 2006 Feb;6(6):495-504. doi: 10.3816/CBC.2006.n.002. Clin Breast Cancer. 2006. PMID: 16595032 Review.

3

Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.

Ocaña A, Amir E. Ocaña A, et al. Cancer Treat Rev. 2009 Dec;35(8):685-91. doi: 10.1016/j.ctrv.2009.08.001. Epub 2009 Sep 4. Cancer Treat Rev. 2009. PMID: 19733440 Review.

4

Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.

Amir E, Ocaña A, Seruga B, Freedman O, Clemons M. Amir E, et al. Among authors: ocana a. Cancer Treat Rev. 2010 Aug;36(5):410-5. doi: 10.1016/j.ctrv.2009.12.012. Epub 2010 Jan 25. Cancer Treat Rev. 2010. PMID: 20100635 Review.

5

Chemotherapy: dose-dense treatment for triple-negative breast cancer.

Amir E, Ocana A, Freedman O, Clemons M, Seruga B. Amir E, et al. Among authors: ocana a. Nat Rev Clin Oncol. 2010 Feb;7(2):79-80. doi: 10.1038/nrclinonc.2009.231. Nat Rev Clin Oncol. 2010. PMID: 20118978 No abstract available.

6

Medical oncology: Zoledronic acid for breast cancer therapy-induced bone loss.

Amir E, Ocaña A, Seruga B, Josse R, Clemons M. Amir E, et al. Among authors: ocana a. Nat Rev Clin Oncol. 2010 Apr;7(4):187-8. doi: 10.1038/nrclinonc.2010.19. Nat Rev Clin Oncol. 2010. PMID: 20354540

7

Targeting DNA repair in breast cancer: a clinical and translational update.

Amir E, Seruga B, Serrano R, Ocana A. Amir E, et al. Among authors: ocana a. Cancer Treat Rev. 2010 Nov;36(7):557-65. doi: 10.1016/j.ctrv.2010.03.006. Epub 2010 Apr 10. Cancer Treat Rev. 2010. PMID: 20385443 Review.

8

Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more?

Seruga B, Ocana A, Niraula S, Amir E. Seruga B, et al. Among authors: ocana a. J Clin Oncol. 2010 Jul 10;28(20):e346-7; author reply e348. doi: 10.1200/JCO.2010.28.3564. Epub 2010 May 10. J Clin Oncol. 2010. PMID: 20458046 No abstract available.

9

Do we have to change the way targeted drugs are developed?

Ocana A, Amir E, Seruga B, Pandiella A. Ocana A, et al. J Clin Oncol. 2010 Aug 20;28(24):e420-1; author reply e422-3. doi: 10.1200/JCO.2010.28.9918. Epub 2010 Jun 21. J Clin Oncol. 2010. PMID: 20567014 Free article. No abstract available.

10

Drug resistance in metastatic castration-resistant prostate cancer.

Seruga B, Ocana A, Tannock IF. Seruga B, et al. Among authors: ocana a. Nat Rev Clin Oncol. 2011 Jan;8(1):12-23. doi: 10.1038/nrclinonc.2010.136. Epub 2010 Sep 21. Nat Rev Clin Oncol. 2011. PMID: 20859283 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

288 results

Search Page

Filters